In the entire cohort, 27 subjects (18%), crossed the level of CK-18 > 200 U/L which is (according to M30 Apoptosense® ELISA assay manufacturer, PEVIVA) the cut-off point indicative for substantial liver disease (for example NASH), if the presence of an epithelial carcinoma is excluded. The gene discussed is KRT18; the disease is metabolic dysfunction-associated steatohepatitis.